Stimulant medications in the management of bulimia nervosa and anorexia nervosa in patients with and without comorbid attention deficit hyperactivity disorder: A systematic review.

Autor: Vickers ML; Metro North Mental Health Service, Herston, Brisbane, Australia; Faculty of Medicine, University of Queensland, Brisbane, Australia; Faculty of Health, Queensland University of Technology, Brisbane, Australia. Electronic address: mark.vickers@uq.net.au., Chan HY; Metro North Mental Health Service, Herston, Brisbane, Australia. Electronic address: byron.chan@health.qld.gov.au., Elliott S; Metro North Mental Health Service, Herston, Brisbane, Australia., Ketheesan S; Metro North Mental Health Service, Herston, Brisbane, Australia; Faculty of Medicine, University of Queensland, Brisbane, Australia., Ramineni V; Metro North Mental Health Service, Herston, Brisbane, Australia., Eriksson L; Herston Health Sciences Library, University of Queensland, Brisbane, Australia., McMahon K; Metro North Mental Health Service, Herston, Brisbane, Australia., Oddy B; Metro North Mental Health Service, Herston, Brisbane, Australia., Scott JG; Child Health Research Centre, The University of Queensland Brisbane, Australia; Child and Youth Mental Health Service, Children's Health Queensland, Brisbane, Australia.
Jazyk: angličtina
Zdroj: Eating behaviors [Eat Behav] 2024 Aug; Vol. 54, pp. 101908. Date of Electronic Publication: 2024 Aug 10.
DOI: 10.1016/j.eatbeh.2024.101908
Abstrakt: Objective: People with attentional problems are at increased risk of eating disorders. This paper aimed to systematically review and synthesize the existing evidence on stimulant medication in the management of patients with bulimia nervosa (BN) or anorexia nervosa (AN) with or without comorbid attention deficit hyperactivity disorder (ADHD).
Method: A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. A protocol for the review was registered with Open Science Framework (OSF) Registry and critical appraisal of the literature was conducted using Joanna Briggs Institute (JBI) Critical Appraisal Tools.
Results: Thirteen articles met inclusion criteria including two quasi-experimental studies, one randomized controlled trial, four case series, and six case reports. 26 cases were included from studies and 32 from case series/reports. Only two cases from a single case report had a diagnosis of AN, while the remainder had BN. Stimulants included methylamphetamine, lisdexamfetamine, methylphenidate, dextroamphetamine sulphate and mixed amphetamine salt. In nearly all cases of BN there were reported reductions in eating disorder symptoms. The rates of adverse effects were high and included weight loss, decreased appetite, tachycardia, dry mouth, fatigue, insomnia, restlessness, nausea, bruxism, headache, palpitations, blood pressure changes, irritability, anxiety, depressed mood, and diaphoresis.
Conclusion: There is currently insufficient evidence to support the use of stimulant medications to treat symptoms of BN or AN. The authors recommend considering screening patients with BN for ADHD.
Competing Interests: Declaration of competing interest The authors have no financial or personal relationships with people or organizations that have inappropriately influenced this work.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: